Based on the Scopus Biopharma Inc stock forecast from 0 analysts, the average analyst target price for Scopus Biopharma Inc is not available over the next 12 months. Scopus Biopharma Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Scopus Biopharma Inc is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Scopus Biopharma Inc’s stock price was USD 0.00. Scopus Biopharma Inc’s stock price has changed by -25.00% over the past week, +0.00% over the past month and -99.29% over the last year.
No recent analyst target price found for Scopus Biopharma Inc
No recent average analyst rating found for Scopus Biopharma Inc
Company Overview Scopus Biopharma Inc
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York. Read Less
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a mas...Read More
Frequently Asked Questions About Scopus Biopharma Inc (SCPS) Stock
Stock Target Advisor's fundamental analysis for Scopus Biopharma Inc's stock is Bearish.
Unfortunately we do not have enough data on SCPS's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SCPS's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on SCPS's stock to indicate if its overvalued.
The last closing price of SCPS's stock was USD 0.00.
The most recent market capitalization for SCPS is USD 0.02M.
Unfortunately we do not have enough analyst data on SCPS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Scopus Biopharma Inc's stock.
As per our most recent records Scopus Biopharma Inc has 13 Employees.
Scopus Biopharma Inc's registered address is 420 Lexington Avenue, New York, NY, United States, 10170.
You can get more information about it from Scopus Biopharma Inc's website at https://scopusbiopharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Scopus Biopharma Inc (SCPS) Stock
Stock Target Advisor's fundamental analysis for Scopus Biopharma Inc's stock is Bearish.
Unfortunately we do not have enough data on SCPS's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on SCPS's stock to indicate what its average analyst target is.
Unfortunately we do not have enough data on SCPS's stock to indicate if its overvalued.
The last closing price of SCPS's stock was USD 0.00.
The most recent market capitalization for SCPS is USD 0.02M.
Unfortunately we do not have enough analyst data on SCPS's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Scopus Biopharma Inc's stock.
As per our most recent records Scopus Biopharma Inc has 13 Employees.
Scopus Biopharma Inc's registered address is 420 Lexington Avenue, New York, NY, United States, 10170.
You can get more information about it from Scopus Biopharma Inc's website at https://scopusbiopharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for SCPS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
